Cargando…

Journey on Naphthoquinone and Anthraquinone Derivatives: New Insights in Alzheimer’s Disease

Alzheimer’s disease (AD) is a progressive neurodegenerative disease that is characterized by memory loss, cognitive impairment, and functional decline leading to dementia and death. AD imposes neuronal death by the intricate interplay of different neurochemical factors, which continue to inspire the...

Descripción completa

Detalles Bibliográficos
Autores principales: Campora, Marta, Francesconi, Valeria, Schenone, Silvia, Tasso, Bruno, Tonelli, Michele
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7824805/
https://www.ncbi.nlm.nih.gov/pubmed/33466332
http://dx.doi.org/10.3390/ph14010033
_version_ 1783640167443070976
author Campora, Marta
Francesconi, Valeria
Schenone, Silvia
Tasso, Bruno
Tonelli, Michele
author_facet Campora, Marta
Francesconi, Valeria
Schenone, Silvia
Tasso, Bruno
Tonelli, Michele
author_sort Campora, Marta
collection PubMed
description Alzheimer’s disease (AD) is a progressive neurodegenerative disease that is characterized by memory loss, cognitive impairment, and functional decline leading to dementia and death. AD imposes neuronal death by the intricate interplay of different neurochemical factors, which continue to inspire the medicinal chemist as molecular targets for the development of new agents for the treatment of AD with diverse mechanisms of action, but also depict a more complex AD scenario. Within the wide variety of reported molecules, this review summarizes and offers a global overview of recent advancements on naphthoquinone (NQ) and anthraquinone (AQ) derivatives whose more relevant chemical features and structure-activity relationship studies will be discussed with a view to providing the perspective for the design of viable drugs for the treatment of AD. In particular, cholinesterases (ChEs), β-amyloid (Aβ) and tau proteins have been identified as key targets of these classes of compounds, where the NQ or AQ scaffold may contribute to the biological effect against AD as main unit or significant substructure. The multitarget directed ligand (MTDL) strategy will be described, as a chance for these molecules to exhibit significant potential on the road to therapeutics for AD.
format Online
Article
Text
id pubmed-7824805
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-78248052021-01-24 Journey on Naphthoquinone and Anthraquinone Derivatives: New Insights in Alzheimer’s Disease Campora, Marta Francesconi, Valeria Schenone, Silvia Tasso, Bruno Tonelli, Michele Pharmaceuticals (Basel) Review Alzheimer’s disease (AD) is a progressive neurodegenerative disease that is characterized by memory loss, cognitive impairment, and functional decline leading to dementia and death. AD imposes neuronal death by the intricate interplay of different neurochemical factors, which continue to inspire the medicinal chemist as molecular targets for the development of new agents for the treatment of AD with diverse mechanisms of action, but also depict a more complex AD scenario. Within the wide variety of reported molecules, this review summarizes and offers a global overview of recent advancements on naphthoquinone (NQ) and anthraquinone (AQ) derivatives whose more relevant chemical features and structure-activity relationship studies will be discussed with a view to providing the perspective for the design of viable drugs for the treatment of AD. In particular, cholinesterases (ChEs), β-amyloid (Aβ) and tau proteins have been identified as key targets of these classes of compounds, where the NQ or AQ scaffold may contribute to the biological effect against AD as main unit or significant substructure. The multitarget directed ligand (MTDL) strategy will be described, as a chance for these molecules to exhibit significant potential on the road to therapeutics for AD. MDPI 2021-01-05 /pmc/articles/PMC7824805/ /pubmed/33466332 http://dx.doi.org/10.3390/ph14010033 Text en © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Campora, Marta
Francesconi, Valeria
Schenone, Silvia
Tasso, Bruno
Tonelli, Michele
Journey on Naphthoquinone and Anthraquinone Derivatives: New Insights in Alzheimer’s Disease
title Journey on Naphthoquinone and Anthraquinone Derivatives: New Insights in Alzheimer’s Disease
title_full Journey on Naphthoquinone and Anthraquinone Derivatives: New Insights in Alzheimer’s Disease
title_fullStr Journey on Naphthoquinone and Anthraquinone Derivatives: New Insights in Alzheimer’s Disease
title_full_unstemmed Journey on Naphthoquinone and Anthraquinone Derivatives: New Insights in Alzheimer’s Disease
title_short Journey on Naphthoquinone and Anthraquinone Derivatives: New Insights in Alzheimer’s Disease
title_sort journey on naphthoquinone and anthraquinone derivatives: new insights in alzheimer’s disease
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7824805/
https://www.ncbi.nlm.nih.gov/pubmed/33466332
http://dx.doi.org/10.3390/ph14010033
work_keys_str_mv AT camporamarta journeyonnaphthoquinoneandanthraquinonederivativesnewinsightsinalzheimersdisease
AT francesconivaleria journeyonnaphthoquinoneandanthraquinonederivativesnewinsightsinalzheimersdisease
AT schenonesilvia journeyonnaphthoquinoneandanthraquinonederivativesnewinsightsinalzheimersdisease
AT tassobruno journeyonnaphthoquinoneandanthraquinonederivativesnewinsightsinalzheimersdisease
AT tonellimichele journeyonnaphthoquinoneandanthraquinonederivativesnewinsightsinalzheimersdisease